other material
confidence high
sentiment positive
materiality 0.65
Adial amends warrant deals to reclassify $22.7M liability to equity, regain Nasdaq compliance
ADIAL PHARMACEUTICALS, INC.
- On Sep 16, 2026, amended Purchase and Note Exchange Agreements to remove Penalty Provision, add lock-up on warrant shares.
- Milestone Warrant rights reclassified from liability to equity: $19.7M (PIPE) and $3.0M (noteholders) to additional paid-in capital.
- Pro forma equity improves from $(38.4M) deficit to $22.9M positive as of Jun 30, 2026.
- Series A Preferred (12,930.617 shares) converts to 12.93M common shares; total common shares pro forma 15.56M.
- Amendments intended to satisfy Nasdaq continued listing and initial listing standards for change of control at Sep 17 Annual Meeting.